BioWorld Science

Feb. 6, 2013

View Archived Issues

Chemokine receptor modulators reported by AstraZeneca

Read More

Neuroprotective glutathione analogues discovered at University of Minnesota

Read More

Lundbeck presents new nAChR positive allosteric modulators

Read More

Knockout model casts doubt on the role of protein kinase M zeta type in memory

Read More

AstraZeneca presents overview of pipeline with 2012 results

Read More

Kyowa Hakko Kirin reviews highlights of 2012

Read More

ALK5 and/or ALK4 inhibitors developed at SK Chemicals

Read More

Merck & Co. presents new FIXa inhibitors

Read More

Sunshine Lake Pharma develops new agents for HCV infection

Read More

Pfizer begins phase I trial of anti-IgE vaccine using Cytos' VLP technology

Read More

Stem Cell Therapeutics and Trillium Therapeutics set to merge

Read More

Ono Pharmaceutical updates progress of third quarter of fiscal 2012

Read More

Biocancell reports data from phase IIb pancreatic cancer study

Read More

Antitrypanosomal reduces experimental pulmonary hypertension and pulmonary fibrosis

Read More

AOD-9604 shows promise in rabbit model of osteoarthritis

Read More

Verastem to evaluate VS-6063 plus paclitaxel in ovarian cancer

Read More

Nektar begins phase II trial of NKTR-102 in non-small cell lung cancer

Read More

RepliCel set to meet with German competent authority for hair cell product trial

Read More

GE Healthcare highlights recently launched technologies targeting cancer

Read More

MVA-85A tuberculosis vaccine well tolerated but not significantly effective in phase IIb trial

Read More

EMA approves label extension for Abilify

Read More

Merck Serono and Opexa Therapeutics enter MS drug agreement

Read More

Agreement entered into on phase II trial of universal factor Xa inhibitor antidote PRT-4445

Read More

Xenon receives Glybera approval milestone payment

Read More

ALK-1 signaling inhibitor dalantercept begins two new phase II trials

Read More